Shares of Check Cap Ltd (NASDAQ:CHEK) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price target of $4.58 for the company and are predicting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 173 out of 265 based on the ratings given to related companies.
A number of equities analysts recently issued reports on CHEK shares. Zacks Investment Research cut shares of Check Cap from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. HC Wainwright upped their price target on shares of Check Cap from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, January 11th.
A hedge fund recently bought a new stake in Check Cap stock. Anson Funds Management LP bought a new stake in shares of Check Cap Ltd (NASDAQ:CHEK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 332,302 shares of the medical research company’s stock, valued at approximately $289,000. Anson Funds Management LP owned 1.73% of Check Cap as of its most recent filing with the Securities and Exchange Commission. 22.18% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Brokerages Expect Check Cap Ltd (CHEK) to Announce ($0.14) Earnings Per Share” was published by WKRB News and is owned by of WKRB News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.wkrb13.com/2018/03/31/brokerages-expect-check-cap-ltd-chek-to-announce-0-14-earnings-per-share.html.
About Check Cap
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.